Top
Summary
All studies
Cases
Peer-reviewed
All outcomes

Feedback
Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
All vitamin K studies
 
Feedback
Home
c19early.org COVID-19 treatment researchVitamin KVitamin K (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

Outcomes in COVID-19 vitamin K studies

0 0.5 1 1.5+ All studies 14% 1 7,766 Improvement, Studies, Patients Relative Risk Cases 14% 1 7,766 Prophylaxis 14% 1 7,766 Vitamin K for COVID-19 c19early.org April 2024 Favorsvitamin K Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Deschasaux-Tanguy 14% 0.86 [0.74-0.99] cases 7,766 (all patients) per SD change Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.04 Prophylaxis 14% 0.86 [0.74-0.99] 14% lower risk All studies 14% 0.86 [0.74-0.99] 14% lower risk 1 vitamin K COVID-19 study c19early.org April 2024 Tau​2 = 0.00, I​2 = 0.0%, p = 0.04 Effect extraction pre-specified(most serious outcome) Favors vitamin K Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Deschasaux-Tanguy 14% 0.86 [0.74-0.99] cases 7,766 (all patients) per SD change Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.04 Prophylaxis 14% 0.86 [0.74-0.99] 14% lower risk All studies 14% 0.86 [0.74-0.99] 14% lower risk 1 vitamin K COVID-19 case result c19early.org April 2024 Tau​2 = 0.00, I​2 = 0.0%, p = 0.04 Favors vitamin K Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Deschasaux-Tanguy 14% 0.86 [0.74-0.99] cases 7,766 (all patients) per SD change Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.04 Prophylaxis 14% 0.86 [0.74-0.99] 14% lower risk All studies 14% 0.86 [0.74-0.99] 14% lower risk 1 vitamin K COVID-19 peer reviewed studies c19early.org April 2024 Tau​2 = 0.00, I​2 = 0.0%, p = 0.04 Effect extraction pre-specified(most serious outcome) Favors vitamin K Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Deschasaux-Tanguy 14% 0.86 [0.74-0.99] cases 7,766 (all patients) per SD change Improvement, RR [CI] Treatment Control Vitamin K COVID-19 outcomes c19early.org April 2024 Favors vitamin K Favors control
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit